Analysts See $0.64 EPS for Norbord (OSB); Biostar Pharmaceuticals (BSPM) Shorts Increased By 2.66%

June 26, 2017 - By Maria Brooks

Biostar Pharmaceuticals Incorporated (NASDAQ:BSPM) had an increase of 2.66% in short interest. BSPM’s SI was 316,200 shares in June as released by FINRA. Its up 2.66% from 308,000 shares previously. With 18,700 avg volume, 17 days are for Biostar Pharmaceuticals Incorporated (NASDAQ:BSPM)’s short sellers to cover BSPM’s short positions. The SI to Biostar Pharmaceuticals Incorporated’s float is 14.41%. The stock increased 4.17% or $0.06 on June 23, reaching $1.5. About shares traded. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) has risen 57.27% since June 26, 2016 and is uptrending. It has outperformed by 40.57% the S&P500.

Analysts expect Norbord Inc (TSE:OSB) to report $0.64 EPS on July, 25.They anticipate $0.15 EPS change or 30.61% from last quarter’s $0.49 EPS. OSB’s profit would be $55.71M giving it 15.62 P/E if the $0.64 EPS is correct. After having $0.58 EPS previously, Norbord Inc’s analysts see 10.34% EPS growth. The stock increased 1.47% or $0.58 on June 23, reaching $39.98. About 56,875 shares traded. Norbord Inc (TSE:OSB) has 0.00% since June 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Norbord Inc. is a Canada-based producer of wood panels. The company has market cap of $3.48 billion. The Firm is engaged in manufacturing, sales, marketing and distribution of panelboards and related products used in the construction of new homes or the renovation and repair of existing structures. It has a 12.46 P/E ratio. The Company’s geographic divisions include North America and Europe.

Among 3 analysts covering Norbord Inc. (TSE:OSB), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Norbord Inc. had 7 analyst reports since May 2, 2016 according to SRatingsIntel. RBC Capital Markets maintained the shares of OSB in report on Wednesday, June 7 with “Top Pick” rating. The firm has “Outperform” rating by Scotia Capital given on Monday, June 27. The rating was downgraded by IBC to “Sector Perform” on Monday, October 24. The company was maintained on Friday, March 10 by Scotia Capital.

Biostar Pharmaceuticals, Inc. is a holding company. The company has market cap of $4.16 million. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, makes and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). It currently has negative earnings. The Firm offers over-the-counter (OTC) products and prescription pharmaceuticals.